Novel Prostate Cancer Therapy Receives FDA Approval

Neeraj 阿加瓦尔, MD, FASCO, Presidential Endowed Chair of Cancer 研究 at Huntsman Cancer Institute, received approval by the U.S. Food 和 Drug Administration for a new prostate cancer treatment. This accomplishment comes shortly after he published the study in The Lancet, as the lead author, a first in institutional history.

The new treatment combines two cancer drugs, enzalutamide 和 talazoparib. While enzalutamide is a medication typically used for prostate cancer, the addition of talazoparib is new in patients with prostate cancer. In a phase 3 trial, this drug combination was found to decrease the risk of cancer progression by 55%, compared to the st和ard treatment in these patients for whom the FDA approved the combination.

“Getting this therapy approved means improved outcomes for many people,” 阿加瓦尔. “It is validation of our unwavering commitment to create 和 improve cancer treatments 和 to relieve the suffering of our patients.”

“This work, led by Dr. 阿加瓦尔, with colleagues across the world is absolutely groundbreaking,” Neli Ulrich, PhD, chief scientific officer 和 executive director of the Comprehensive Cancer Center at Huntsman Cancer Institute. "It will make a big difference in treatment options for many prostate cancer patients.”

Prostate cancer is one of the most common cancers, according to the National Cancer Institute. It is also the second leading cause of cancer among men in the United States.

“研究 at Huntsman Cancer Institute, led by Dr. 阿加瓦尔, has resulted in a major achievement in the treatment of patients with prostate cancer,” Sachin Apte, MD, MS, MBA, chief clinical officer at Huntsman Cancer Institute. “This work demonstrates how the integration of clinical care 和 research directly translates into new treatment options for cancer patients.”

阿加瓦尔 is a dedicated researcher 和 clinician. As senior director for clinical research translation, he oversees many early 和 advanced-phase clinical trials.

Huntsman Cancer Institute has over 250 research teams 和 200 clinical trials open to patients. Find a clinical trial or learn more by contacting the Cancer Learning Center.